OCUL Ocular Therapeutix

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025.

Upcoming Scientific Conferences (all times ET):

American Academy of Optometry: October 8 - 11, 2025

Boston, Massachusetts

  • Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Phase 1 Trial

    Session Date/Time: Thursday, October 9, 2025, 4:30 – 6:30 PM ET

    Presenter: Trung Tran, OD, Senior Medical Director at Ocular Therapeutix

Eyecelerator @ AAO 2025: October 16, 2025

Orlando, Florida

  • Company Presentation: Ocular Therapeutix: Redefining the Retina Experience

    Session: Presenting Company Showcases

    Session Date/Time: Thursday, October 16, 2025, 1:15 – 2:45 PM ET

    Presenter: Peter K. Kaiser, MD, Chief Development Officer

American Academy of Ophthalmology: October 18 - 20, 2025

Orlando, Florida

  • On-Demand Poster Title: Macular Fluid Volume and Retinal Vascular Leakage Analysis Following a Single Axitinib Intravitreal Hydrogel in Diabetic Retinopathy

    Session Date/Time: On-demand posters available for viewing throughout duration of the congress.

    Presenter: Margaret Chang, MD, MS

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with a Phase 3 clinical program for non-proliferative diabetic retinopathy (NPDR) planned to be initiated imminently.

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Explore the Company’s new corporate branding and follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media

Ocular Therapeutix, Inc.

Bill Slattery

Vice President, Investor Relations



EN
07/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocular Therapeutix

 PRESS RELEASE

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences BEDFORD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in October 2025. Upcoming Scientific Conferences (all times ET): American Academy of Optometry: October 8 - 11, 2025Boston, Massachusetts Poster Title: Safety and Efficacy of OTX-TKI in Moderately Severe to Severe NPDR: One Year Results from the HELIOS Ph...

 PRESS RELEASE

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Comm...

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced the pricing of an underwritten offering of 37,909,018 shares of its common stock at an offering price of $12.53 per share for gross proceeds of approximately $475.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. All of the sh...

 PRESS RELEASE

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Pro...

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint SOL-1 superiority trial continues to demonstrate outstanding patient retention and protocol adherence, with no new or unexpected safety signals observed to date; topline data on track for 1Q 2026 Event to detail how robust SOL-R patient selection strategy, trial design, and potential SOL-1 success could drive confidence in SOL-R outcomes; topline data on track for 1H 2027 Will showcase plan...

 PRESS RELEASE

Ocular Therapeutix™ to Host Investor Day on September 30, 2025

Ocular Therapeutix™ to Host Investor Day on September 30, 2025 Company to highlight ongoing AXPAXLI™ wet AMD registrational program, strategy and next steps in NPDR and DME, and global commercial opportunity for AXPAXLI Event to feature global retinal disease experts Dr. Arshad M. Khanani MD, MA, FASRS; Professor Adnan Tufail, MBBS, MD, FRCOphth; Dr. Eleonora Lad, MD, PhD; and Dr. Patricio G. Schlottmann, MD The live event will take place in New York City on September 30, 2025, at 2:00 PM ET BEDFORD, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL...

 PRESS RELEASE

Ocular Therapeutix™ to Participate in September Investor and Scientifi...

Ocular Therapeutix™ to Participate in September Investor and Scientific Conferences BEDFORD, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September 2025. Upcoming Investor Conferences Morgan Stanley 23rd Annual Global Healthcare Conference:Fireside Chat Date/Time: Monday, September 8, 2025Fireside Chat Time: 2:35 – 3:10 PM ETPresenter: Pravin U. Dugel, MD, Executi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch